Related Experiment Video
Updated: Jun 17, 2026
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Hearing outcome after Cyberknife® radiotherapy for vestibular Schwannoma
Manon Bachelet1, Romain Tournegros1, Maxime Fieux2,3,4
1Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, Pierre Bénite cedex, F-69495, France.
Purpose:
The main objective was to evaluate the hearing impairment of patients after hypofractionated stereotactic radiotherapy (HSRT) by CyberKnife® for vestibular schwannoma (VS).
Methods:
Patients treated by HSRT with CyberKnife® for sporadic progressive VS between January 2010 and February 2020 with at least 1 year follow-up were included. Exclusion criteria were pre-treatment cophosis, lack of at least one pre- and post-irradiation hearing test, a history of treatment of the VS. Bilateral pure-tone testing and speech testing, magnetic resonance imaging (MRI) characteristics of the VS (volume, Koos classification, fundus and internal auditory canal invasion), and HSRT characteristics (80% isodose, number of fractions, dose per fraction, mean cochlear dose) were collected before HSRT and at 1, 3, and 5 years follow-up.
Results:
71 patients with a 1-year follow-up were included, 55 patients had a 3-year follow-up, and 34 had a 5-year follow-up; the mean follow-up was 43 months (± 24). During the entire follow-up, 89% of the patients (63/71) had hearing impairment, which occurred during the first year for 79% (56/71) of the patients. No risk factor among age, MRI characteristics, and HSRT modalities were found to be associated with hearing impairment in the first year. No relationship was found between tumor volume and hearing impairment.
Conclusion:
For most patients, HSRT is responsible for hearing impairment within the first year.
Trial Registration Number:
#20-84 on September the 10th, 2021.
